Integer Holdings' (ITGR) Q4 Earnings Beat, '19 View Strong

Integer Holdings Corporation ITGR reported fourth-quarter 2018 adjusted earnings of $1.04 per share, which surpassed the Zacks Consensus Estimate of 92 cents. The bottom line also increased 8.3% on a year-over-year basis.

Revenues decreased 22.4% year over year to $303 million on a reported basis but outshined the Zacks Consensus Estimate of $298 million.

Additionally, Integer Holdings’ share price inched up owing to upbeat 2019 earnings guidance. For 2019, adjusted earnings are expected in the range of $4.05-$4.25 per share, indicating a 7-12% increase from the previous year. The mid-point of the latest guidance range of $4.15 beats the Zacks Consensus Estimate of $4.08.

On a reported basis, Integer Holdings expects 2019 earnings are anticipated in the $2.77-$2.97 per share band, mirroring 7-12% growth year over year.

Integer Holdings Corporation Price and Consensus

 

Integer Holdings Corporation Price and Consensus | Integer Holdings Corporation Quote

2018 at a Glance

In 2018, Integer Holdings registered revenues of $1.22 billion on a GAAP basis, improving 6.9% on a reported basis and 7.1% on an organic basis year over year. However, the top line missed the Zacks Consensus Estimate of $1.30 billion.

Total Medical sales in the year were $1.16 billion (95.1% of net revenues), while Non-medical sales were almost $53 million (4.9% of net revenues).

Segmental Analysis

Integer Holdings operates through two segments — Medical Sales and Non-Medical Sales.

Medical Sales

At the segment, reported revenues were $290.2 million, up 0.9% year over year. Revenues increased 1.6% on an organic basis.

Medical Sales has three sub-segments — Advanced Surgical, Orthopedics and Portable Medical (AS&O); Cardio and Vascular; and Cardiac/Neuromodulation.

Advanced Surgical, Orthopedics and Portable Medical

Integer Holdings’ Advanced Surgical, Orthopedics & Portable Medical segment has been divested to Viant. Thus, revenues at the segment include net sales from the acquirer Viant under supply agreements associated with the divestiture.

Revenues amounted to $31.7 million, down 0.4% from the prior-year quarter. Notably, the metric grew 4.8% on an organic basis. Per management, the upside was driven by solid market demand.

Cardio and Vascular

Revenues at the segment totaled $149.6 million, up 7.7% from the prior-year quarter and 8% organically. Per management, revenues increased primarily on continued strong demand in the electrophysiology market and product launches.

Cardiac/Neuromodulation

Revenues at this segment summed $108.9 million, down 6.7% from the prior-year quarter. On an organic basis, revenues at the segment decreased 6.7% year over year.

Non-Medical Sales

Reported revenues at the segment totaled $12.8 million, down 13.2% on both year over year and organic basis. Per management, the downturn was caused due to North American drilling activity and planned phase out of certain rechargeable battery pack products.

Margin Analysis

Integer Holdings generated a gross profit of $88.4 million in the fourth quarter, down 5.5% year over year. As a percentage of revenues, gross margin in quarter contracted 180 basis points (bps) to 29.2%.

Selling, general and administrative expenses (SG&A) were $35.1 million, down 7.7% year over year.

Research, development and engineering costs grossed $10.2 million in the quarter, down 26.1% year over year.

Total operating income amounted to $39.7 million, up 32.9% year over year. Adjusted income from operations totaled $25.3 million, up 55.6% year over year.

Adjusted operating margin was 8.4%, up 300 bps year over year.

Guidance

For 2019, Integer Holdings expects reported revenues between $1.26 billion and $1.28 billion, reflecting year-over-year growth of 4-5%. On an adjusted basis, the company expects revenues in the same band, mirroring a 4-6% improvement from the previous year. Notably, the mid-point of the guidance is in line with the Zacks Consensus Estimate of $1.27 billion.

Adjusted income from operations is anticipated between $141 million and $275 million, indicating a year-over-year rise of 8-13%.

Summing Up

Integer Holdings exited the fourth quarter on a solid note, beating the Zacks Consensus Estimate on both the counts.

The Zacks Rank #3 (Hold) company continues to gain from its Cardio & Vascular product line. Strong demand across key areas like electrophysiology, structural heart and peripheral vascular is an added positive. Management is optimistic about the divestiture of its AS&O product line. An upbeat outlook for 2019 and expansion in operating margin buoy optimism on the stock. Integer Holdings also paid down its debt significantly in the last reported quarter.

On the flip side, Integer Holdings’ Non-Medical segment continues to see market softness. Management expects segment revenues to be flat year over year in the next quarter. Gross margin contraction adds to the woes.

Earnings of MedTech Majors at a Glance

Some better-ranked MedTech stocks that posted solid quarterly results are Varian Medical Systems VAR, AngioDynamics ANGO and CONMED Corporation CNMD.

Varian reported fiscal first-quarter adjusted EPS of $1.06, in line with the Zacks Consensus Estimate. Revenues of $741 million outpaced the consensus mark of $717.9 million. The stock has a Zacks Rank #2 (Buy).

AngioDynamics’ fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, which surpassed the consensus estimate by 2.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million exceeded the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
 
AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report
 
Varian Medical Systems, Inc. (VAR) : Free Stock Analysis Report
 
CONMED Corporation (CNMD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.